Navigation Links
Hypertension Drug Market Will Experience Only Modest Annual Decline Through 2018, Despite Generic Erosion Of Many Branded Agents
Date:8/25/2009

WALTHAM, Mass., Aug. 25 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that despite generic erosion of many branded agents -- most notably Novartis's Diovan -- the hypertension drug market will experience only modest decline over the next decade. Through 2013, the market will decrease by 1.4 percent annually and thereafter the annual decline will slow to 1 percent through 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Hypertension finds that the major contributor to market decline will be the increasing generic availability of antihypertensive agents. By 2018, Diovan alone will lose more than $1 billion in sales, owing to generic erosion of the agent which will begin in 2010 in the U.S., in 2011 in Europe and in 2013 in Japan. Additionally, agents from drug classes that are typically used in first-, second-, and third-line therapy -- such as angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor antagonists (AIIRAs), calcium-channel blockers (CCBs), and diuretics -- will all be subject to generic competition.

The report also finds that near-term opportunity in the hypertension market -- which is saturated with effective, well-established treatments -- lies in the development of therapies that offer greater convenience. Fixed-dose combinations such as CCB/renin-angiotensin-aldosterone system (RAAS) inhibitors and CCB/RAAS/diuretics will capitalize on this opportunity. By 2012, three fixed-dose combinations -- Novartis's Exforge HCT, Daiichi Sankyo's olmesartan/amlodipine/HCT, and Novartis's aliskiren/amlodipine/HCT -- will each be available in the world's major markets. While these agents will offer considerable improvements in convenience over currently available fixed-dose combinations, interviewed experts express differing views on their likely uptake.

"Some experts welcome the greater convenience of these combination therapies which could help reduce patients' pill burden," said Decision Resources Analyst Caroline Gates. "However, others indicate that they prefer to use single agents in order to titrate individual doses on a patient-by-patient basis, especially in cases of advanced hypertension where at least three antihypertensive agents are typically required to control blood pressure."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    Decision Resources                Decision Resources, Inc.
    Christopher Comfort               Elizabeth Marshall
    781-296-2597                      781-296-2563
    ccomfort@dresources.com           emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom
2. Presentation of Phase IIa Results for Cytos Biotechnologys Hypertension Vaccine at the American Heart Association Scientific Sessions 2007
3. Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
4. Experts and Representatives From Leading International Health-Care Organizations Call to Stop the Hypertension Pandemic, a Worldwide Silent Killer
5. Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for First Product, CloniBID, to Treat Hypertension
6. Pulmonary Hypertension Association Names Recipient of 2008 Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care
7. Addrenex Pharmaceuticals Licenses New Compound to Sciele Pharma for the Treatment of Hypertension and Other Potential Indications
8. Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH
9. Sinobiopharma Announces SFDA Approval of Anti-Hypertension Drug Perindopril
10. Pulmonary Hypertension Association Names Dr. Nicholas Hill Recipient of 2009 Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care
11. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Calif. , Feb. 11, 2016  Dovetail Genomics™ ... to its beta program for a planned metagenomic genome ... present the company,s metagenomic genome assembly method in a ... in Genome Biology & Technology conference in ... of these highly complex datasets is difficult. Using its ...
(Date:2/11/2016)... ... , ... Global Stem Cells Group, a world ... Cells Network (GSCN) to distribute exosome injection and other biological products to stem ... Dominican Republic, Colombia, Argentina, Nicaragua, Panama, El Salvador, Venezuela, Peru, Ecuador, Paraguay, Puerto ...
(Date:2/10/2016)... ANNAPOLIS, Md. , Feb. 10, 2016  The ... E. Busch , has announced that University of Maryland ... MD, PhD, MBA and University of Maryland Medical System ... recipients of the "Speaker,s Medallion," the highest honor given ... House of Delegates. Dean Reece and ...
(Date:2/10/2016)... 2016  IsoRay, Inc. (NYSE MKT: ISR), a medical ... radioisotope applications for the treatment of prostate, brain, lung, ... financial results for the second quarter and six months ... --> --> Revenue ... 2016, which ended December 31, 2015, a 12% increase ...
Breaking Biology Technology:
(Date:2/2/2016)... Feb. 2, 2016  BioMEMS devices deployed ... focused on medical screening and diagnostic applications, ... Wearable devices that facilitate and assure continuous ... movement are being bolstered through new opportunities ... signal acquisition coupled with wireless connectivity and ...
(Date:2/2/2016)... RESTON, Va. , Feb. 2, 2016 /PRNewswire/ ... contract award from the U.S. Army Research Office ... extend the range and sensitivity of the company,s ... DoD,s Past Accounting Mission and, more generally, defense-related ... its DNA phenotyping capabilities (predicting appearance and ancestry ...
(Date:2/1/2016)... ( www.wocketwallet.com ) announces the launch of a new video featuring singer, ... Las Vegas , where Joey appeared at the Wocket booth to ... , where Joey appeared at the Wocket booth to meet and greet ... the Consumer Electronics Show (CES2016) in Las Vegas , ... --> --> The video is ...
Breaking Biology News(10 mins):